Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 16 years, with Q2 2025 value amounting to -$2.3 million.

  • Lifecore Biomedical, Inc. \De\'s Change in Inventory fell 84563.11% to -$2.3 million in Q2 2025 from the same period last year, while for May 2025 it was -$7.7 million, marking a year-over-year decrease of 79187.94%. This contributed to the annual value of -$7.7 million for FY2025, which is 79187.94% down from last year.
  • Lifecore Biomedical, Inc. \De\'s Change in Inventory amounted to -$2.3 million in Q2 2025, which was down 84563.11% from -$4.6 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Change in Inventory registered a high of $12.2 million during Q4 2022, and its lowest value of -$8.2 million during Q2 2022.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Change in Inventory had a median value of -$140000.0 in 2023 and averaged $353833.3.
  • Within the past 5 years, the most significant YoY rise in Lifecore Biomedical, Inc. \De\'s Change in Inventory was 95833.33% (2024), while the steepest drop was 89508.2% (2024).
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Change in Inventory (Quarter) stood at $9.5 million in 2021, then rose by 27.44% to $12.2 million in 2022, then crashed by 102.01% to -$244000.0 in 2023, then crashed by 895.08% to -$2.4 million in 2024, then rose by 5.11% to -$2.3 million in 2025.
  • Its Change in Inventory stands at -$2.3 million for Q2 2025, versus -$4.6 million for Q1 2025 and -$2.4 million for Q4 2024.